Astaxanthin

Safety Risk (2.0/5.0). One of the cleaner safety profiles in the supplement space. Brendler 2019's review of 87 human studies (including 35 at >=12 mg/day up to 40 mg/day for 90 days) reported zero serious adverse events. No deaths, no hospitalizations, no organ failure from monotherapy. FDA FAERS and CAERS show no signal. EFSA set an ADI of 14 mg/day for a 70 kg adult and approved 8 mg/day supplements for adults and adolescents 14+. The one documented serious AE is Santiyanon and Yeephu 2019's warfarin interaction case (INR 1.4 to 10.38 in 48 hours at 8 mg/day, fully reversed with vitamin K): a pharmacodynamic interaction, not intrinsic toxicity. The BioHarmony catastrophic floor targets intrinsic risks and does not fire for co-medication-mediated AEs. The largest gap in the profile is absence of long-term data above 20 mg/day beyond 12 weeks.

Side Effect Profile (1.5/5.0). All mild, all reversible. Across RCTs: GI upset (bloating, loose stool) in 1-3% of participants, usually when taken on an empty stomach; occasional red-orange stool color at high doses; mild headache 1-2% (usually in cognition trials); carotenoderma (yellow-orange palm and sole tint) above approximately 12 mg/day after 3-4 weeks of chronic use, purely cosmetic and clearing within 2-3 weeks of discontinuation; a meta-analytic ALT elevation of about +1.92 U/L that is statistical but not clinically significant; mild DBP lowering of 1-3 mmHg. Reddit and Examine user reports match the trial literature closely: "mild, safe, maybe underwhelming at low dose." No tolerance buildup, no rebound effects on cessation, no pattern of emergent long-tail AEs across the 25+ year commercial history.

Financial Cost (1.8/5.0). Quality natural astaxanthin (BioAstin, AstaReal, Nutrex Hawaii, Algatech AstaPure) runs roughly $15-30 per month at 12 mg/day. Per v0.5 accessible-channel scoring rules, this is the price we score against because bulk retail channels are a false economy: NOW Foods' 2023 retail testing found 14 of 22 samples failed potency, meaning the $5-12/month "bargain" bottles are often delivering 0-30% of labeled content. Affordable enough to sit in most supplement stacks without displacing priorities. Not HSA-eligible in most US plans. No insurance coverage. Stackable with magnesium, creatine, omega-3, and most other foundational nutrients without meaningful interaction cost.

Time/Effort Burden (1.0/5.0). One capsule with any meal containing fat, typically breakfast. There is no protocol to learn, no injection, no prep, no cycling requirement, no timing around training or sleep. Daily friction is under five seconds. Per v0.5 effort-dimension standards, this sits at the substrate-class floor alongside creatine, magnesium glycinate, and taurine. The only adherence hook is remembering the fat co-ingestion step: taken fasted, absorption drops 3-5x (Odeberg 2003), so deliberate meal-pairing is the one behavioral lever that matters. Compare with protocols like cold exposure (15+ min dedicated time), neurofeedback (20-30 min sessions), or BFR training (learned setup and supervision): astaxanthin is effectively zero-effort once the meal-pairing habit is installed.

Opportunity Cost (1.2/5.0). Astaxanthin complements nearly everything: other antioxidants, omega-3, creatine, polyphenols, sleep and training protocols. It does not crowd out other interventions or demand behavioral bandwidth. The only mild overlap is with high-dose mixed carotenoid formulas (beta-carotene, lutein, zeaxanthin), where absorption competition at the enterocyte level has been documented, and with high-dose mixed tocopherol E that can blunt the in-vivo antioxidant delta. Neither is a deal-breaker; dose-separate by several hours if stacking. There is no opportunity cost against "doing it right" fundamentals (sleep, training, nutrition, sunlight) the way high-maintenance interventions create. The dimension score reflects near-zero displacement of better interventions.

Dependency/Withdrawal (1.0/5.0). No known dependency or withdrawal mechanism. You can stop at any time with no rebound, no cravings, no HPG downregulation, no receptor desensitization. Per v0.5 substrate-class dependency framework, this is the floor: astaxanthin is a pure dietary substrate that integrates into the membrane antioxidant pool and is replaced by endogenous tissue redox machinery on cessation. No published case reports of discontinuation syndrome. No community anecdote of a withdrawal pattern. No receptor mechanism for physiological dependency to form. This is structurally identical to the dependency profile of vitamin C, magnesium glycinate, or dietary fatty acids.

Reversibility (1.0/5.0). Fully reversible. Plasma levels clear in approximately 72-96 hours after the last dose per Odeberg 2003 pharmacokinetic data, erythrocyte levels in roughly 2 weeks given the ~28-hour RBC half-life, and tissue stores in the hippocampus, cortex, retinal pigment epithelium, and skin clear over weeks to a few months depending on compartment turnover. No permanent physiological changes, no epigenetic imprints, no receptor downregulation, no HPA axis recalibration, no structural membrane modification beyond the transient lipid-embedded fraction. Contrast with pharmaceutical interventions like SSRIs or GLP-1 agonists where cessation can drive rebound hyperphagia or emotional withdrawal: astaxanthin cessation produces only a gradual, asymptotic return to baseline oxidative-stress markers over 4-8 weeks.